Domov › Akútna myeloidná leukémia › Iowa
Klinické štúdie Akútna myeloidná leukémia v štáte Iowa
17 štúdií pre Akútna myeloidná leukémia hľadá účastníkov v zariadeniach v štáte Iowa.
Mestá v štáte Iowa
Oficiálny text štúdie (anglicky)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- a 12 ďalších
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Vek 40 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive
- Iowa Methodist Medical Center, Des Moines
- a 7 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Prebieha náborFáza 2
Vek 18 až 59 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Prebieha náborFáza 3
6 Months – 21 Years · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Iowa Hospital, Iowa City
Prebieha náborFáza 1/2
30 Days · Všetky pohlavia · Aktualizované 16. 9. 2026 · NCT04065399Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Blank Children's Hospital, Des Moines
Prebieha náborFáza 3
Vek 1 až 25 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07022678A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Iowa Hospital and Clinics, Iowa City
Prebieha náborObservačná štúdia
Vek 0 a viac · Všetky pohlavia · Aktualizované 2. 9. 2026 · NCT07154823High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
- University of Iowa Health Care, Iowa City
Prebieha náborFáza 1
Vek 18 až 75 · Všetky pohlavia · Aktualizované 31. 8. 2026 · NCT07177079The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Prebieha náborFáza 1/2
Do veku 22 · Všetky pohlavia · Aktualizované 25. 8. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- University of Iowa Stead Family Children's Hospital, Iowa City
Prebieha náborFáza 3
29 Days – 21 Years · Všetky pohlavia · Aktualizované 24. 8. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Iowa, Iowa City
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- University of Iowa Hospitals & Clinics, Iowa City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 20. 8. 2026 · NCT06001788Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- University of Iowa Hospitals and Clinics, Iowa City
Prebieha náborFáza 3
Vek 18 až 75 · Všetky pohlavia · Aktualizované 17. 7. 2026 · NCT05429632A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Iowa, Iowa City
Prebieha náborObservačná štúdia
Všetky vekové kategórie · Všetky pohlavia · Aktualizované 6. 7. 2026 · NCT01351545A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Iowa Hospitals & Clinics, Iowa City
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 3. 2026 · NCT05735184Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.